Advertisement
"We are very pleased with the progress of the collaboration with Pfizer,"said John K. Westwick, Ph.D., Odyssey Thera's President and CEO. "Progress onthis and other discovery programs with Pfizer demonstrates the power of ourunique cellular analysis platform to improve knowledge of drug mechanisms andselectivity."
Advertisement
In August 2006, Odyssey Thera announced its third alliance with Pfizer.Under the terms of the multi-year agreement, Odyssey Thera is collaborating onmultiple Pfizer drug discovery projects, and has received upfront payments,research and capital expenditure funding, and previous success-basedmilestones. The achievement of this milestone announced today is the Company'sfirst such milestone to be earned for contributing to the advancement of adrug candidate.
About Odyssey Thera, Inc.
Odyssey Thera's patented technology measures disease-relevant pathwayactivity within living human cells. Rapid identification of on-target andoff-pathway activities of lead compounds enables selection of drug candidateswith favorable safety and selectivity profiles. Odyssey is leveraging itsproprietary drug discovery and development platform for internal programs andfor premier pharmaceutical company partners.
To learn more about Odyssey Thera, please visithttp://www.odysseythera.com
SOURCE Odyssey Thera, Inc.